Aggrenox Buyers Blast Discovery Bid In Antitrust MDL
Direct purchasers in multidistrict litigation accusing Boehringer Ingelheim Pharmaceuticals Inc. of scheming to keep generic versions of the stroke-prevention drug Aggrenox off the market slammed discovery requests regarding several other drugs...To view the full article, register now.
Already a subscriber? Click here to view full article